secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001558370-24-009282
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure CMO Han Myint retires July 1; becomes consultant through 2025
----------------------------------------------------------------------

- Dr. Han Myint retires as CMO effective July 1, 2024; will provide consulting services starting July 2, 2024 on clinical trials and join Scientific Advisory Board.
- The Company will provide continued salary and healthcare benefits through March 31, 2025.
- Equity awards continue to vest during the consulting term; exercisability period extended to 90 days after term expiration.
- Consulting agreement initial term through July 2, 2025, auto-renewing annually unless terminated by either party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024009282/0001558370-24-009282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024009282/nxtc-20240618x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer